L’activité exceptionnelle du DNV3681 contre des menaces bioterroristes présentée à l’ASM Microbe 2019
24 juin 2019 12h00 HE
|
Deinove
L’activité exceptionnelle du DNV3681 contre des menaces bioterroristes présentée à l’ASM Microbe 2019 Le Major Steven Zumbrun (USAMRIID1, Département de la Défense des Etats-Unis) a présenté la...
DNV3681's exceptional activity against bioterrorist threats presented at ASM Microbe 2019
24 juin 2019 12h00 HE
|
Deinove
DNV3681's exceptional activity against bioterrorist threats presented at ASM Microbe 2019 Major Steven Zumbrun (USAMRIID1, U.S. Department of Defense) presented data on the in vitro assessment of...
Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD)
24 mars 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, March 24, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that the European subsidiary, "Hemispherx Biopharma Europe...
Hemispherx Biopharma to Present Data on the Activity of Ampligen(R) Against the Ebola Virus
23 mars 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, March 23, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") will present integrated findings of new studies of Ampligen®...
Hemispherx Biopharma and USAMRIID to Present New Discoveries Concerning the Efficacy of Ampligen(R) Against the Ebola Virus at Upcoming International Symposium on Filoviruses
12 févr. 2015 08h30 HE
|
AIM ImmunoTech Inc.
Ampligen® May Be an Important Candidate for EBOV Testing in West Africa
PHILADELPHIA, Feb. 12, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or...
Hemispherx: U.S. Army Scientists (USAMRIID) Find Ampligen(R) Produces 100% Survival Rate in Ebola Virus Rodent Study
02 févr. 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Feb. 2, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today the results of a new efficacy study of Ampligen® in a...
USAMRIID Reports Genetic Changes in Ebola Virus May Impede Potential Treatments
26 janv. 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 26, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today that in a new publication in the journal mBio, scientists at...
Hemispherx Announces Data Showing Inhibition of Ebola by Ampligen(R) Enlarged by Howard University Research
09 déc. 2014 09h51 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Dec. 9, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today that it has received a new research report (dated December 5,...
Hemispherx Biopharma and United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Collaborate on Alferon(R) and Ampligen(R) Against the Ebola Virus
03 nov. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Nov. 3, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), has been informed by USAMRIID scientists that they have in-vitro data...